Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1532

1.

Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by arresting T cell activation.

Jachetti E, Caputo S, Mazzoleni S, Brambillasca CS, Parigi SM, Grioni M, Piras IS, Restuccia U, Calcinotto A, Freschi M, Bachi A, Galli R, Bellone M.

Cancer Res. 2015 Mar 25. pii: canres.2346.2014. [Epub ahead of print]

PMID:
25808872
2.

Gene and Protein Expression of Fibronectin and Tenascin-C in Lung Samples from COPD Patients.

Muñoz-Esquerre M, Huertas D, Escobar I, López-Sánchez M, Penín R, Peinado V, Barberà JA, Molina-Molina M, Manresa F, Dorca J, Santos S.

Lung. 2015 Mar 21. [Epub ahead of print]

PMID:
25794567
3.

Tenascin-X: beyond the architectural function.

Valcourt U, Alcaraz LB, Exposito JY, Lethias C, Bartholin L.

Cell Adh Migr. 2015 Jan 2;9(1-2):154-65. doi: 10.4161/19336918.2014.994893.

PMID:
25793578
4.

Tenascin-C and carcinoma cell invasion in oral and urinary bladder cancer.

Berndt A, Richter P, Kosmehl H, Franz M.

Cell Adh Migr. 2015 Jan 2;9(1-2):105-11. doi: 10.1080/19336918.2015.1005463.

PMID:
25793577
5.

Tenascin-C and integrins in cancer.

Yoshida T, Akatsuka T, Imanaka-Yoshida K.

Cell Adh Migr. 2015 Jan 2;9(1-2):96-104. doi: 10.1080/19336918.2015.1008332.

PMID:
25793576
6.

Transcriptional regulation of tenascin genes.

Chiovaro F, Chiquet-Ehrismann R, Chiquet M.

Cell Adh Migr. 2015 Jan 2;9(1-2):34-47. doi: 10.1080/19336918.2015.1008333.

PMID:
25793574
7.

Qingre Quyu Granule () stabilizes plaques through inhibiting the expression of tenascin-C in patients with severe carotid stenosis.

Wang Y, Cheng WL, Wang Y, Peng JP, Yuan J, Chen L, Pan L, Li H, Guo J.

Chin J Integr Med. 2015 Mar 17. [Epub ahead of print]

PMID:
25776840
8.

Tenascin-C Levels, A Toll-like Receptor 4 Ligand, in Enthesitis-related Arthritis Category of Juvenile Idiopathic Arthritis: A Cross-sectional and Longitudinal Study.

Shukla A, Gaur P, Aggarwal A.

J Rheumatol. 2015 Mar 15. pii: jrheum.141365. [Epub ahead of print]

PMID:
25774061
9.

Recurrent gastrointestinal perforation in a patient with Ehlers-Danlos syndrome due to tenascin-X deficiency.

Sakiyama T, Kubo A, Sasaki T, Yamada T, Yabe N, Matsumoto KI, Futei Y.

J Dermatol. 2015 Mar 13. doi: 10.1111/1346-8138.12829. [Epub ahead of print]

PMID:
25772043
10.

Tenascin C in metastasis: A view from the invasive front.

Lowy CM, Oskarsson T.

Cell Adh Migr. 2015 Jan 2;9(1-2):112-24. doi: 10.1080/19336918.2015.1008331.

PMID:
25738825
11.

PET Imaging of Tenascin-C with a Radiolabeled Single-Strand DNA Aptamer.

Jacobson O, Yan X, Gang N, Weiss ID, Ma Y, Szajek LP, Shen B, Kiesewetter DO, Chen X.

J Nucl Med. 2015 Feb 19. pii: jnumed.114.149484. [Epub ahead of print]

PMID:
25698784
12.

Tenascin-C induces resistance to apoptosis in pancreatic cancer cell through activation of ERK/NF-κB pathway.

Shi M, He X, Wei W, Wang J, Zhang T, Shen X.

Apoptosis. 2015 Feb 18. [Epub ahead of print]

PMID:
25690319
13.

ADAM-9 is a novel mediator of tenascin-C-stimulated invasiveness of brain tumor-initiating cells.

Sarkar S, Zemp FJ, Senger D, Robbins SM, Yong VW.

Neuro Oncol. 2015 Feb 1. pii: nou362. [Epub ahead of print]

PMID:
25646025
14.

Spatial organization of the tenascin-C microenvironment in experimental and human cancer.

Spenlé C, Gasser I, Saupe F, Janssen KP, Arnold C, Klein A, van der Heyden M, Mutterer J, Neuville-Méchine A, Chenard MP, Guenot D, Esposito I, Slotta-Huspenina J, Ambartsumian N, Simon-Assmann P, Orend G.

Cell Adh Migr. 2015 Jan 2;9(1-2):4-13. doi: 10.1080/19336918.2015.1005452.

PMID:
25611571
15.

Inhibition of fibrous adhesion formation in the temporomandibular joint of tenascin-C knockout mice.

Shinohara Y, Okamoto K, Goh Y, Kiga N, Tojyo I, Fujita S.

Eur J Histochem. 2014 Oct 22;58(4):2337. doi: 10.4081/ejh.2014.2337.

16.

Tenascin-C: Exploitation and collateral damage in cancer management.

Spenlé C, Saupe F, Midwood K, Burckel H, Noel G, Orend G.

Cell Adh Migr. 2015 Jan 2;9(1-2):141-53. doi: 10.1080/19336918.2014.1000074.

PMID:
25569113
17.

Tenascin C levels in patients with mild and severe preeclampsia.

Orak U, Celik E, Kavak SB, Demirel İ, Atilgan R, Aydin S, Sapmaz E.

J Matern Fetal Neonatal Med. 2015 Jan 8:1-4. [Epub ahead of print]

PMID:
25567561
18.

Tenascin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy.

Franz M, Jung C, Lauten A, Figulla HR, Berndt A.

Cell Adh Migr. 2015 Jan 2;9(1-2):90-5. doi: 10.1080/19336918.2014.1000075.

PMID:
25562641
19.

Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C.

Magnusson MK, Strid H, Isaksson S, Bajor A, Lasson A, Ung KA, Öhman L.

J Crohns Colitis. 2015 Jan;9(1):56-65. doi: 10.1093/ecco-jcc/jju008. Epub 2014 Nov 26.

PMID:
25518051
20.

Targeting the fibronectin type III repeats in tenascin-C inhibits epithelial-mesenchymal transition in the context of posterior capsular opacification.

Tiwari A, Ram J, Luthra-Guptasarma M.

Invest Ophthalmol Vis Sci. 2014 Dec 16;56(1):272-83. doi: 10.1167/iovs.14-14934.

PMID:
25515583
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk